Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,042
  • Shares Outstanding, K 56,975
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,680 K
  • EBIT $ 5 M
  • EBITDA $ 5 M
  • 60-Month Beta 3.36
  • Price/Sales 1.88
  • Price/Cash Flow N/A
  • Price/Book 1.01

Options Overview Details

View History
  • Implied Volatility 214.85% (-6.39%)
  • Historical Volatility 59.98%
  • IV Percentile 77%
  • IV Rank 36.74%
  • IV High 492.91% on 04/23/25
  • IV Low 53.32% on 08/19/25
  • Expected Move (DTE 28) 0.64 (27.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 21
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 5,188
  • Open Int (30-Day) 5,091
  • Expected Range 1.66 to 2.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 6
  • High Estimate -0.12
  • Low Estimate -0.23
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.13 +7.98%
on 02/12/26
2.70 -14.81%
on 01/29/26
-0.26 (-10.16%)
since 01/16/26
3-Month
2.13 +7.98%
on 02/12/26
4.05 -43.28%
on 11/20/25
-1.59 (-40.87%)
since 11/19/25
52-Week
1.20 +91.67%
on 04/09/25
4.94 -53.44%
on 11/12/25
-0.07 (-2.95%)
since 02/19/25

Most Recent Stories

More News
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new...

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing...

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...

BDTX : 2.30 (+1.77%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments...

BDTX : 2.30 (+1.77%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities...

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTX : 2.30 (+1.77%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 2.30 (+1.77%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 2.40
2nd Resistance Point 2.35
1st Resistance Point 2.33
Last Price 2.30
1st Support Level 2.25
2nd Support Level 2.20
3rd Support Level 2.17

See More

52-Week High 4.94
Fibonacci 61.8% 3.51
Fibonacci 50% 3.07
Fibonacci 38.2% 2.63
Last Price 2.30
52-Week Low 1.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar